ARKRAY京都 血糖仪GT-1640

ARKRAY京都 血糖仪GT-1640

ARKRAY京都 血糖仪GT-1640

  • 商品品牌: ARKRAY京都
    商品编号:GT-1640
  • 商品价格: 请与我们联系
  • ARKRAY京都 血糖仪GT-1640-ARKRAY京都-GT-1640

    • 最少样本量:3微升
    • 品牌属性:进口
    生命科学仪器|||生化免疫|||血糖分析仪|||ARKRAY京都血糖仪GT-1640
    血糖分析仪

    京都血糖仪GT-1640 详细描述:

    操作简便,精准度高,重复性高无需按钮,无需擦洗,不浪费试纸。

    试纸条单条包装,储存期长,满足各年龄糖尿病人,随时检测血糖的需要,

    多数病友评价甚好,其产品堪称性价比最高的血糖仪!


    商品属性

    • 最少样本量:3微升
    • 品牌属性:进口
    商品属性
    商品名称 ARKRAY京都 血糖仪GT-1640-GT-1640-ARKRAY京都
    型号 GT-1640
    类别 生命科学仪器|||生化免疫|||血糖分析仪|||ARKRAY京都血糖仪GT-1640
    品牌 ARKRAY京都
    品牌简介 ARKRAY京都
    关键字 血糖分析仪,京都,试纸,血糖,血糖仪,样本,时间

    ARKRAY京都 血糖仪GT-1640

    台式高速离心机GT10-2

    【简单介绍】

    品牌 其他品牌 结构类型 台式
    布局形式 立式

    台式高速离心机GT10-2,是医疗卫生、食品、环保、科研、教学优选的离心分离设备。性能好,品质保证,能满足您不同环境的实验需求。
    转速可达10000r/min
    标配10ml×24角转子
    多种规格转子、适配器供选择;

    【详细说明】

    台式高速离心机GT10-2

    产品特点:
        直流无刷电机,免维护;微电脑控制,可预选转速、时间、离心力,液晶显示,操作简便;10种升降速率供选择,可快速启动、快速停机;不锈钢容器室,电子门锁,预警报警功能,多种保护,安全可靠。是医疗卫生、食品、环保、科研、教学的优选离心设备。

    技术参数

    Z高转速

    10000r/min

    Z大相对离心力

    11000×g

    外形尺寸  

    51×41×31(cm)

    定时范围 

    1~999min

    电源 

    AC220V 50Hz 8A

    重量 

    36kg

    台式高速离心机GT10-2

     

    GT10-2转子

    容量

    高转速

    备注

     

    10ml×24

    10000r/min

    标配

     

    100ml×4

    10000r/min

    选配

     

    10ml×12

    10000r/min

    选配
     

    15ml×12

    10000r/min

    选配
     

    50ml×6

    10000r/min

    选配

     

    型号

    高转速

    大离心力

    定时范围

    外形尺寸

    重量

    GT10-1

    10000r/min

    11000×g

    0-999min

    51×41×31(cm)

    32kg

    GT10-2

    10000r/min

    11000×g

    0-999min

    51×41×31(cm)

    32kg

     

    BMS-986144

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

    BMS-986144 

    BMS-986144 是第三代泛基因型 NS3/4A 蛋白酶抑制剂。BMS-986144 抑制 GT-1a,GT-1b,GT-2a,GT-3a,1a R155X,1b D168V 复制子的 EC50 值分别为 2.3,0.7,1.0,12,8.0,5.8 nM。BMS-986144 具有研究 HCV 感染的潜力。

    BMS-986144

    BMS-986144 Chemical Structure

    CAS No. : 1606150-08-6

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection[1].

    分子量

    856.94

    Formula

    C40H48D3F4N5O9S

    CAS 号

    1606150-08-6

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.

    参考文献
    • [1]. Sun LQ, et al. Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection [published online ahead of print, 2020 Nov 23]. J Med Chem. 2020;10.1021/acs.jmedchem.0c01296.

    所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

    Trilaciclib hydrochloride(Synonyms: G1T28 hydrochloride)

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

    Trilaciclib hydrochloride (Synonyms: G1T28 hydrochloride) 纯度: 99.24%

    Trilaciclib hydrochloride (G1T28 hydrochloride) 是 CDK4/6 的抑制剂,对 CDK4 和 CDK6 的 IC50 值分别为 1 nM 和 4 nM。

    Trilaciclib hydrochloride(Synonyms: G1T28 hydrochloride)

    Trilaciclib hydrochloride Chemical Structure

    CAS No. : 1977495-97-8

    规格 价格 是否有货 数量
    1 mg ¥500 In-stock
    5 mg ¥1400 In-stock
    10 mg ¥2000 In-stock
    50 mg ¥6400 In-stock
    100 mg ¥9900 In-stock
    200 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    Trilaciclib hydrochloride 相关产品

    相关化合物库:

    • Drug Repurposing Compound Library Plus
    • FDA-Approved Drug Library Plus
    • Bioactive Compound Library Plus
    • Cell Cycle/DNA Damage Compound Library
    • Kinase Inhibitor Library
    • FDA-Approved Drug Library
    • Anti-Cancer Compound Library
    • Anti-Aging Compound Library
    • Drug Repurposing Compound Library
    • FDA Approved & Pharmacopeial Drug Library
    • Anti-Breast Cancer Compound Library
    • Anti-Pancreatic Cancer Compound Library
    • Anti-Blood Cancer Compound Library

    生物活性

    Trilaciclib hydrochloride (G1T28 hydrochloride) is a CDK4/6 inhibitor with IC50s of 1 nM and 4 nM for CDK4 and CDK6, respectively[1].

    IC50 & Target

    Cdk4/cyclin D1

    1 nM (IC50)

    cdk6/cyclin D3

    4 nM (IC50)

    体外研究
    (In Vitro)

    Incubation with Trilaciclib hydrochloride (G1T28) for 24 hours induces a robust G1 cell-cycle arrest (time=0). By 16 hours after Trilaciclib hydrochloride washout, cells have reentered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells. These results demonstrate that Trilaciclib hydrochloride causes a transient, and reversible G1 arrest. A transient Trilaciclib hydrochloride-mediated G1 cell-cycle arrest in CDK4/6-sensitive cells decreases the in vitro toxicity of a variety of commonly used cytotoxic chemotherapy agents associated with myelosuppression[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    体内研究
    (In Vivo)

    Trilaciclib hydrochloride (G1T28) treatment results in a robust and dose-dependent suppression of proliferation in HSPCs at 12 hours, with 5-ethynyl-2′-deoxyuridine (EdU) incorporation returning near baseline levels in a dose-dependent manner by 24 hours after administration. These data demonstrate that a single oral dose of Trilaciclib hydrochloride can produce reversible cell-cycle arrest in HSPCs in a dose-dependent manner in vivo. Mice given 100 mg/kg Trilaciclib hydrochloride 30 minutes prior to etoposide treatment, exhibits only background levels of caspase-3/7 activity. These data demonstrate that Trilaciclib hydrochloride can protect the bone marrow from chemotherapy-induced apoptosis in vivo. The data demonstrate that treatment with Trilaciclib hydrochloride prior to 5-fluorouracil (5-FU) likely decreases 5-FU-induced damage by chemotherapy in HSPCs, thus accelerating blood count recovery after chemotherapy[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial

    分子量

    519.47

    Formula

    C24H32Cl2N8O

    CAS 号

    1977495-97-8

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    溶解性数据
    In Vitro: 

    H2O : 25.64 mg/mL (49.36 mM; ultrasonic and adjust pH to 2 with HCl)

    DMSO : 1.1 mg/mL (2.12 mM; Need ultrasonic)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 1.9250 mL 9.6252 mL 19.2504 mL
    5 mM 0.3850 mL 1.9250 mL 3.8501 mL
    10 mM 0.1925 mL 0.9625 mL 1.9250 mL

    *

    请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

    参考文献
    • [1]. Bisi JE, et al. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93.

    Kinase Assay
    [1]

    HS68, WM2664, and A2058 cells are treated with 300 nM Trilaciclib hydrochloride (G1T28) or DMSO (0.1%), for 4, 8, 16, or 24 hours. Whole cell extracts are prepared using 1× radioimmunoprecipitation assay buffer containing 1× HALT protease and phosphatase inhibitors. Total protein concentration is determined by using the kit, according to the manufacturer’s instructions. For Western blot analysis, protein is processed as described previously. Antibodies to total RB and β-tubulin run as a loading control are assessed[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [1]

    HS68 cells are treated for 24 hours with Trilaciclib hydrochloride (G1T28) at 10, 30, 100, 300, 1,000, or 3,000 nM final concentration. Cells are harvested and fixed in ice-cold methanol. Fixed cells are stained with 20 μg propidium iodide, 50 μg RNAse A in PBS-CMF (calcium magnesium free) +1% BSA, Fraction V. Samples are processed on Cyan ADP Analyzer, and cell-cycle analysis is completed using software[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Female athymic nude mice are implanted with H69 cells and monitored until treatment initiation. Once tumors reach an acceptable size (150 mm3), mice are dosed in various combinations of Trilaciclib hydrochloride (G1T28) and topotecan for 5 days per week for 4 weeks. Tumors are measured for up to 60 days after treatment. All mice that reach excessive tumor burden before 60 days are humanely euthanized. Topotecan and Trilaciclib hydrochloride levels in blood plasma from the mice treated with Trilaciclib hydrochloride and/or topotecan are processed and analyzed using established methods[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    参考文献
    • [1]. Bisi JE, et al. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93.

    所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

    生物活性分子抑制剂Proxalutamide(Synonyms: GT0918; Pruxelutamide)

    生物活性分子抑制剂 特异性抑制剂 激动剂 化合物库 重组蛋白 Proxalutamide (Synonyms: GT0918; Pruxelutamide) 纯度: 98.79%

    Proxalutamide (GT0918) 是具有口服活性的雄激素受体 (AR) 的拮抗剂。Proxalutamide (GT0918) 可用于前列腺癌和COVID-19的研究。

    Proxalutamide(Synonyms: GT0918;  Pruxelutamide)

    Proxalutamide Chemical Structure

    CAS No. : 1398046-21-3

    规格 价格 是否有货 数量
    10 mM * 1 mL in DMSO ¥5690 In-stock
    5 mg ¥5000 In-stock
    10 mg ¥8500 In-stock
    25 mg ¥18000 In-stock
    50 mg ¥30000 In-stock
    100 mg   询价  
    200 mg   询价  

    * Please select Quantity before adding items.

    Proxalutamide 相关产品

    相关化合物库:

    • Drug Repurposing Compound Library Plus
    • Clinical Compound Library Plus
    • Bioactive Compound Library Plus
    • Anti-Infection Compound Library
    • Anti-Cancer Compound Library
    • Clinical Compound Library
    • Antiviral Compound Library
    • Drug Repurposing Compound Library
    • Transcription Factor Targeted Library

    生物活性

    Proxalutamide (GT0918) is an orally active potent androgen receptor (AR) antagonist. Proxalutamide (GT0918) can be used in the study for prostate cancer and COVID-19[1][2][3][4][5].

    IC50 & Target

    Androgen Receptor[1].

    体外研究
    (In Vitro)

    Proxalutamide (GT0918) down-regulates AR protein level in prostate cancer cells[1].
    Proxalutamide can overcome the resistance of prostatic cancer cells by downregulating the expression of AR genes[4].
    Proxalutamide (GT0918, 0-200 μM) dose-dependently inhibits cell viability in LNCaP and 22RV1[5].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[5].

    Cell Line: Four human PCa cell lines, LNCaP, 22RV1, PC3 and DU145.
    Concentration: 1, 2, 5, 10, 20, 50, 100, and 200 μM.
    Incubation Time: Up to 72 h.
    Result: Preferentially affected AR-positive PCa cells (IC50 values from 6.90 to 32.07 μM) over AR-negative cells (IC50 > 200 μM).

    体内研究
    (In Vivo)

    The elimination half-life (t1/2) of proxalutamide in rats is approximately 2 h regardless of whether it is administered by the intragastric or the intravenous route. The maximum plasma concentration of proxalutamide (Cmax) could reach 2 μg/mL or higher, and the oral absolute bioavailability (F) was approximately 80%[4].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Rats[4].
    Dosage: 20 mg/kg (Pharmacokinetic Analysis).
    Administration: Intragastrically.
    Result: T1/2 = 2 h and F% = 80%

    Clinical Trial

    分子量

    517.50

    Formula

    C24H19F4N5O2S

    CAS 号

    1398046-21-3

    中文名称

    普克鲁胺

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性数据
    In Vitro: 

    DMSO : 100 mg/mL (193.24 mM; Need ultrasonic)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 1.9324 mL 9.6618 mL 19.3237 mL
    5 mM 0.3865 mL 1.9324 mL 3.8647 mL
    10 mM 0.1932 mL 0.9662 mL 1.9324 mL

    *

    请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

    In Vivo:

    请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
    分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 1.

      请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: 2.5 mg/mL (4.83 mM); Suspended solution; Need ultrasonic

      此方案可获得 2.5 mg/mL (4.83 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

      以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

      将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

    • 2.

      请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: 2.5 mg/mL (4.83 mM); Suspended solution; Need ultrasonic

      此方案可获得 2.5 mg/mL (4.83 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

      以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

      将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
    • 3.

      请依序添加每种溶剂: 10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (4.83 mM); Clear solution

      此方案可获得 ≥ 2.5 mg/mL (4.83 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

      以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

    *以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
    参考文献
    • [1]. Youzhi Tong, et al. Abstract 614: Proxalutamide (GT0918), a potent androgen receptor pathway inhibitor. Cancer Research. AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA.

      [2]. Yang M, et al. Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: preparation, characterization and evaluation in vivo. Int J Pharm. 2014 Nov 20;475(1-2):97-109.

      [3]. Monitoring Editor, et al. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial. Cureus. 2021 Feb; 13(2): e13492.

      [4]. Hua Sang, et al. Quantitative determination of proxalutamide in rat plasma and tissues using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2021 Feb 15;35(3):e9003.

      [5]. Feng Qu, et al. Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells. Invest New Drugs. 2020 Oct;38(5):1292-1302.

    所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

    德国CMVC离心机CMVC GT

    德国CMVC离心机CMVC GT

  • 品牌 CMVC|CMVC
  • 型号 CMVC GT
  • 货号 EY0107
  • 商品详情

    产品详情

    ◎ 德国制造

    ◎ 微处理器控制

    ◎ 可永久性安装在滚轴上或从滚轴上拆除

    ◎ 无需维修,无刷感应式驱动

    ◎ 不锈钢腔室,外加额外的内部保护环

    ◎ 超速检测,不平衡检测和断电

    ◎ 彩色大屏液晶显示当前和预设数值,包括速度、重力、时间和温度

    技术参数:

    德国CMVC离心机CMVC GT

    德国CMVC离心机CMVC GT

  • Lerociclib dihydrochloride(Synonyms: G1T38 dihydrochloride)

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

    Lerociclib dihydrochloride (Synonyms: G1T38 dihydrochloride) 纯度: 99.74%

    Lerociclib dihydrochloride (G1T38 dihydrochloride) 是一种有效的选择性 CDK4/CDK6 抑制剂,抑制 CDK4/CyclinD1CDK6/CyclinD3IC50 值分别为 1 nM 和 2 nM。

    Lerociclib dihydrochloride(Synonyms: G1T38 dihydrochloride)

    Lerociclib dihydrochloride Chemical Structure

    CAS No. : 2097938-59-3

    规格 价格 是否有货 数量
    5 mg ¥4800 In-stock
    10 mg ¥7500 In-stock
    25 mg ¥14500 In-stock
    50 mg   询价  
    100 mg   询价  

    * Please select Quantity before adding items.

    Lerociclib dihydrochloride 相关产品

    相关化合物库:

    • Drug Repurposing Compound Library Plus
    • Clinical Compound Library Plus
    • Bioactive Compound Library Plus
    • Cell Cycle/DNA Damage Compound Library
    • Kinase Inhibitor Library
    • Anti-Cancer Compound Library
    • Clinical Compound Library
    • Anti-Aging Compound Library
    • Drug Repurposing Compound Library
    • Anti-Breast Cancer Compound Library
    • Anti-Lung Cancer Compound Library
    • Anti-Pancreatic Cancer Compound Library
    • Anti-Blood Cancer Compound Library

    生物活性

    Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 1 nM and 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.

    IC50 & Target[1]

    Cdk4/cyclin D1

    1 nM (IC50)

    cdk6/cyclin D3

    2 nM (IC50)

    CDK9/Cyclin T

    28 nM (IC50)

    CDK5/p35

    832 nM (IC50)

    Cdk5/p25

    1.2 μM (IC50)

    cdk2/cyclin A

    1.5 μM (IC50)

    CDK2/cyclinE

    3.6 μM (IC50)

    CDK1/cyclinB1

    2.4 μM (IC50)

    CDK7/Cyclin H/MAT1

    2.4 μM (IC50)

    体外研究
    (In Vitro)

    Within the CDK family, Lerocyclib is least selective against CDK9/cyclin T, ~30 fold between CDK4/cyclin D1 and CDK9/ cyclin T at the biochemical IC50. Lerociclib produces a robust and sustained G1 arrest in CDK4/6 dependent cells with an EC50 of ~20 nM. A dose dependent increase of cells in the G1 phase of the cell cycle is observed when CDK4/6 dependent WM2664 cells are treated with G1T38 for 24 hours. This arrest is maintained through 300 nM, more than 300x the biochemical IC50. WM2664 cells treated with 30-1000 nM of Lerociclib for 24 hours exhibits a complete inhibition of RB phosphorylation compared to vehicle controls. Treatment with G1T38 reduces RB phosphorylation within 1 hour post-treatment and generates near complete inhibition of RB phosphorylation by 16 hours post-treatment. G1T38 produces a robust inhibition of proliferation in a diverse array of tumor cell lines including breast, melanoma, leukemia and lymphoma with EC50 concentrations as low as 23 nM[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    体内研究
    (In Vivo)

    In this HER2+ breast cancer model, Mice treated with Lerociclib elicits 8% tumor regression after 21 days of treatment while control animals have a 577% increase in tumor burden over the same treatment period. Compared to the vehicle-treated mice, daily treatment with 100 mg/kg of Lerociclib or palbociclib shows tumor regression within 10 days in the MCF7 xenograft model. After 27 days of treatment, tumor growth inhibition is observed in the 10, 50, and 100 mg/kg Lerociclib cohorts (approximately 12%, 74%, and 90% inhibition, respectively). Daily oral palbociclib treatment causes an 18%, 66%, and 87% tumor growth inhibition in the 10, 50, and 100 mg/kg dosage cohorts, respectively. Interestingly, at 50 mg/kg, Lerociclib is significantly more efficaciou than palbociclib. Similar results are seen in the ER+ ZR-75-1 breast cancer xenograft model when comparing Lerocyclib and palbociclib at the 50 mg/kg dose. Lerociclib treated mice exhibits 77% TGI with an overall 60% tumor growth delay demonstrating Lerociclib alone is highly efficacious in this NSCLC tumor model[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial

    分子量

    547.52

    Formula

    C26H36Cl2N8O

    CAS 号

    2097938-59-3

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    溶解性数据
    In Vitro: 

    H2O : 4 mg/mL (7.31 mM; Need ultrasonic)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 1.8264 mL 9.1321 mL 18.2642 mL
    5 mM 0.3653 mL 1.8264 mL 3.6528 mL
    10 mM

    *

    请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

    参考文献
    • [1]. Bisi JE, et al. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget. 2017 Jun 27;8(26):42343-42358.

    Cell Assay
    [1]

    SupT1, Daudi, MCF7, ZR-75-1, A2058, WM2664, and H69 cells are seeded at 1000 cells per well; MV-4-11 and BV173 cells are plated at 4000 cells per well; Tom-1 cells are plated at 8,000 cells per well; NALM-1 cells are plated at 20,000 cells per well in Costar 3903 96 well plates. After 24 hours, plates are dosed with Lerociclib at a nine-point dose concentration from 10 μM to 1 nM. Cell viability is determined after four or six days. Plates are processed on BioTek Synergy2 multi-mode plate reader and data analyzed using GraphPad Prism 5 statistical software[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Mice[1]
    Female MMTV-NEU mice are used to test the efficacy of Lerociclib (100 mpk, medicated diet). At time of treatment, body composition is assessed and weight measurements (in grams) are recorded and used as a measure of gross toxicity. Female nude mice are implanted with NSCLC PDX CTG0159 tumor. Mice are then randomized into treatment groups and dosing initiated once tumors reached a volume that fell within the range of 150-300 mm3. 100 mg/kg Lerociclib or vehicle is orally administered for 28 consecutive days. Female NCI Ath/nu mice are implanted with H1975 NSC lung adenocarcinoma model. Once tumors reach an average size of 100-150 mm3, mice are randomized into treatment cohorts. Mice are orally administered daily Afatinib (20 mg/kg), Erlotinib (70 mg/kg), or Lerociclib (50 or 100 mg/kg), as single agents or in combination (Lerociclib+Erlotinib or Lerociclib+Afatinib) for the duration of the study. All tumors are measured twice weekly until mice reach tumor burden of 1500 mm3.

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    参考文献
    • [1]. Bisi JE, et al. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget. 2017 Jun 27;8(26):42343-42358.

    所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

    ARKRAY京都 血糖仪GT-1920

    ARKRAY京都 血糖仪GT-1920

    ARKRAY京都 血糖仪GT-1920

  • 商品品牌: ARKRAY京都
    商品编号:GT-1920
  • 商品价格: 请与我们联系
  • ARKRAY京都 血糖仪GT-1920-ARKRAY京都-GT-1920

    • 最少样本量:0.3微升
    • 测定时间:≤10S
    • 品牌属性:进口
    生命科学仪器|||生化免疫|||血糖分析仪|||ARKRAY京都血糖仪GT-1920
    血糖分析仪

    ARKRAY京都 血糖仪GT-1920 详细描述:

    操作简单

    性价比高

    高速测定 极微量采血

    商品属性

    • 最少样本量:0.3微升
    • 测定时间:≤10S
    • 品牌属性:进口
    商品属性
    商品名称 ARKRAY京都 血糖仪GT-1920-GT-1920-ARKRAY京都
    型号 GT-1920
    类别 生命科学仪器|||生化免疫|||血糖分析仪|||ARKRAY京都血糖仪GT-1920
    品牌 ARKRAY京都
    品牌简介 ARKRAY京都
    关键字 血糖分析仪,京都,样本,时间,血糖仪,血糖,性价比

    ARKRAY京都 血糖仪GT-1920

    ARKRAY京都 血糖仪GT-1640

    ARKRAY京都 血糖仪GT-1640

    ARKRAY京都 血糖仪GT-1640

  • 商品品牌: ARKRAY京都
    商品编号:GT-1640
  • 商品价格: 请与我们联系
  • ARKRAY京都 血糖仪GT-1640-ARKRAY京都-GT-1640

    • 最少样本量:3微升
    • 品牌属性:进口
    生命科学仪器|||生化免疫|||血糖分析仪|||ARKRAY京都血糖仪GT-1640
    血糖分析仪

    京都血糖仪GT-1640 详细描述:

    操作简便,精准度高,重复性高无需按钮,无需擦洗,不浪费试纸。

    试纸条单条包装,储存期长,满足各年龄糖尿病人,随时检测血糖的需要,

    多数病友评价甚好,其产品堪称性价比最高的血糖仪!


    商品属性

    • 最少样本量:3微升
    • 品牌属性:进口
    商品属性
    商品名称 ARKRAY京都 血糖仪GT-1640-GT-1640-ARKRAY京都
    型号 GT-1640
    类别 生命科学仪器|||生化免疫|||血糖分析仪|||ARKRAY京都血糖仪GT-1640
    品牌 ARKRAY京都
    品牌简介 ARKRAY京都
    关键字 血糖分析仪,京都,试纸,血糖,血糖仪,样本,时间

    ARKRAY京都 血糖仪GT-1640

    Rintodestrant(Synonyms: G1T48)

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

    Rintodestrant (Synonyms: G1T48)

    Rintodestrant (G1T48) 是具有口服活性的、非甾体类的、选择性的雌激素受体 (estrogen receptor) 的降解剂。Rintodestrant (G1T48) 也是 CDK4/6 的抑制剂。

    Rintodestrant(Synonyms: G1T48)

    Rintodestrant Chemical Structure

    CAS No. : 2088518-51-6

    规格 价格 是否有货
    5 mg ¥5000 询问价格 & 货期
    10 mg ¥8500 询问价格 & 货期

    * Please select Quantity before adding items.

    生物活性

    Rintodestrant (G1T48) is an orally active, non-steroidal and selective estrogen receptor degrader. Rintodestrant (G1T48) is also a CDK4/6 inhibitor[1].

    体外研究
    (In Vitro)

    Rintodestrant (G1T48) is a potent and efficacious inhibitor of estrogen-mediated transcription and proliferation in ER-positive breast cancer cells, similar to the pure antiestrogen fulvestrant[1].
    Rintodestrant (G1T48) selectively inhibits the growth of ER-positive, but not ER-negative, breast cancer cells[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[1]

    Cell Line: MCF7 cells.
    Concentration: 1 pM-1 μM.
    Incubation Time: 18 h.
    Result: Downregulates the estrogen receptor in breast cancer cells.
    Significantly inhibited estrogen-mediated growth of MCF7 cells demonstrating approximately threefold higher potency when compared to Fulvestrant.
    Does not impact apoptosis in MCF7 breast cancer cells.

    体内研究
    (In Vivo)

    Rintodestrant (G1T48, 30 or 100 mg/kg) inhibits estrogen signaling in endocrine-resistant breast cancer models[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: MCF7 xenograft tumors[1].
    Dosage: 30 or 100 mg/kg.
    Administration: P.O. daily for 28 days.
    Result: Demonstrated dose-dependent inhibition of TamR tumor growth.

    分子量

    462.49

    Formula

    C26H19FO5S

    CAS 号

    2088518-51-6

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.

    参考文献
    • [1]. Kaitlyn J Andreano, et al. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Res Treat. 2020 Apr;180(3):635-646.

    所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

    ARKRAY京都 血糖仪GT-1820

    ARKRAY京都 血糖仪GT-1820

    ARKRAY京都 血糖仪GT-1820

  • 商品品牌: ARKRAY京都
    商品编号:GT-1820
  • 商品价格: 请与我们联系
  • ARKRAY京都 血糖仪GT-1820-ARKRAY京都-GT-1820

    • 最少样本量:0.6微升
    • 测定时间:≤10S
    • 品牌属性:进口
    生命科学仪器|||生化免疫|||血糖分析仪|||ARKRAY京都血糖仪GT-1820
    血糖分析仪


     京都血糖仪GT-1820 详细描述:

     试纸弹出器,可自动退片;

     业内首创,自动校正血容积;

     高速,极微量采血。


    商品属性

    • 最少样本量:0.6微升
    • 测定时间:≤10S
    • 品牌属性:进口
    商品属性
    商品名称 ARKRAY京都 血糖仪GT-1820-GT-1820-ARKRAY京都
    型号 GT-1820
    类别 生命科学仪器|||生化免疫|||血糖分析仪|||ARKRAY京都血糖仪GT-1820
    品牌 ARKRAY京都
    品牌简介 ARKRAY京都
    关键字 血糖分析仪,京都,样本,时间,血糖仪,试纸,容积

    ARKRAY京都 血糖仪GT-1820

    GT16-3高速台式离心机

    【简单介绍】

    品牌 其他品牌 结构类型 台式
    布局形式 立式

    产品编号:GT16-3(原LG16-3)高速台式离心机
    GT16-3高速台式离心机,微电脑控制,可预选转速、时间、离心力,操作简便;10种升降速率,可快速启动、停机;不锈钢容器室,电子门锁,是医疗卫生、食品、环保、科研、教学优选的离心机分离设备。
    现货常备

    【详细说明】

    GT16-3高速台式离心机

    产品简述:

      GT16-3(原LG16-3)实验室高速台式离心机(标配1.5ml×12转子)采用直流无刷电机,免维护;微电脑控制,可预选转速、时间、离心力,液晶显示,操作简便;预警报警、多种保护;10种升降速率供选择;可快速启动,快速停机;不锈钢容器室,电子门锁,安全可靠;是医疗卫生、食品、环保、科研、教学优选的离心机分离设备。

    主要技术参数:

    z高转速Max Speed        16000r/min

    z大相对离心力 Max RCF   18000×g

    定时范围 Time Range       1-999min

    电源 Power Supply         AC220V  50Hz  8A

    外形尺寸 Dimension        37×29×26cm

    重量 Wight                24kg

    容量 Capacity             1.5/2ml×12角转子

                              0.5ml×12角转子(选配)

                              5 ml×12角转子(13000r/min选配)

                                 7 ml×10角转子(13000r/min选配)

                                 1.5ml×24角转子(13000r/min选配)

                                 0.5ml×48角转子(选配)

    应用领域:

       GT16-3高速台式离心机广泛适用于中心血站、血库、医院检验、放免及高校、教研实验、农业科学、生物工程、环保等领域。

     

    产品图片:

    相关产品:

    型号

    配置

    产品名称

    功能特点

    z高转速(r/min)

    z大离心力(×g)

    容量

    (ml)

    说明

    DT5-1

    A

    原LD4-2A

    低速台式

    离心机

    无刷电机,微电脑控制,可预选转速、时间、离心力,全液显

    4000

    2860

    100ml×4

    标配

     

     

     

     

     

     

    10ml×12

    标配

     

     

     

     

     

     

    10ml(锥形管)×8

    选配

     

    B

    低速台式

    离心机

     

    4000

    2860

    7ml /10ml×24

    标配

    DT5-2

    A

    原LD5-2A

    低速台式

    离心机

    无刷电机,微电脑控制,可预选转速、时间、离心力,全液显,不锈钢容器室

    5000

    4360

    100ml×4

    标配

     

     

     

     

    5000

     

    10ml×12

    标配

     

     

     

     

    3500

     

    10ml×32

    标配

     

     

     

     

    5000

     

    10ml(锥形管)×8

    选配

     

    B

    低速台式

    离心机

     

    5000

    4360

    100ml×4

    标配

     

     

     

     

    4200

     

    50ml(锥形管)×8

    标配

     

     

     

     

    4200

     

    15ml(锥形管)×16

    标配

     

     

     

     

    4200

     

    15ml(锥形管)×24

    选配

     

    美容离心机

     

    5000

     

    50ml(注射器)×4

    标配

    DT5-3

    A

     

    原LDZ5-2

    低速台式自动平衡离心机

    无刷电机,微电脑控制,可预选转速、时间、离心力,全液晶显示,不锈钢容器室

    3500

    4360

    10ml×32

    标配

     

     

     

     

    4200

     

    2ml/5ml×40

    (75mm采血管)

    标配

     

     

     

     

    4200

     

    5ml/7ml×48

    (105mm采血管)

    标配

     

     

     

     

    5000

     

    100ml×4

    选配

     

     

     

     

    5000

     

    10ml×12

    选配

     

     

     

     

    4200

     

    7ml×60

    选配

     

     

     

     

    2000

     

    96孔培养板

    选配

    DT5-3

     

    血库通用

    离心机

    微电脑控制,7个预选程序,分离到秒,快速启动快速停机。

    5000

    4360

    100ml×4

    标配

    GT10-1/GT10-2(原LG10-2.4A)实验室高速台式离心机

    【简单介绍】

    品牌 SartoriusSigma

    GT10-1/GT10-2(原LG10-2.4A)实验室高速台式离心机,采用微电脑控制,可预选转速、时间、离心力,液晶显示,操作简便;预警报警、多种保护;10种升降速率供选择,可快速启动,快速停机;不锈钢容器室,电子门锁,安全可靠。是医疗卫生、食品、环保、科研、教学优选的离心机分离设备。

    【详细说明】

    GT10-1/GT10-2(原LG10-2.4A)实验室高速台式离心机

    产品简述:

      GT10-1/GT10-2(原LG10-2.4A)实验室高速台式离心机采用直流无刷电机,免维护;微电脑控制,可预选转速、时间、离心力,液晶显示,操作简便;预警报警、多种保护;10种升降速率供选择,可快速启动,快速停机;不锈钢容器室,电子门锁,安全可靠。是医疗卫生、食品、环保、科研、教学优选的离心机分离设备。

    这两个型号的主机是一样的,区别是所标配的转子不同:

    GT10-1台式高速离心机:标配50ml×6角转子

    GT10-1台式高速离心机:标配10ml×24角转子

    主要技术参数:

    高转速Max Speed        10000r/min

    大相对离心力 Max RCF   11000×g

    定时范围 Time Range       1-999min

    电源 Power Supply         AC220V  50Hz  8A

    外形尺寸 Dimension        51×41×31cm

    重量 Wight                36kg

    容量 Capacity             50ml×6角转子

                              10ml×24角转子(选配)

                               15ml×12角转子(选配)

                               100ml×4角转子(选配)

    应用领域:

       广泛适用于中心血站、血库、医院检验、放免及高校、教研实验、农业科学、生物工程、环保等领域。

    产品图片:

    相关产品:

    型号

    配置

    产品名称

    功能特点

    高转速(r/min)

    大离心力(×g)

    容量

    (ml)

    说明

    DT5-1

    A

    原LD4-2A

    低速台式

    离心机

    无刷电机,微电脑控制,可预选转速、时间、离心力,全液显

    4000

    2860

    100ml×4

    标配

    10ml×12

    标配

    10ml(锥形管)×8

    选配

    B

    低速台式

    离心机

    4000

    2860

    7ml /10ml×24

    标配

    DT5-2

    A

    原LD5-2A

    低速台式

    离心机

    无刷电机,微电脑控制,可预选转速、时间、离心力,全液显,不锈钢容器室

    5000

    4360

    100ml×4

    标配

    5000

    10ml×12

    标配

    3500

    10ml×32

    标配

    5000

    10ml(锥形管)×8

    选配

    B

    低速台式

    离心机

    5000

    4360

    100ml×4

    标配

    4200

    50ml(锥形管)×8

    标配

    4200

    15ml(锥形管)×16

    标配

    4200

    15ml(锥形管)×24

    选配

    美容离心机

    5000

    50ml(注射器)×4

    标配

    DT5-3

    A

    原LDZ5-2

    低速台式自动平衡离心机

    无刷电机,微电脑控制,可预选转速、时间、离心力,全液晶显示,不锈钢容器室

    3500

    4360

    10ml×32

    标配

    4200

    2ml/5ml×40

    (75mm采血管)

    标配

    4200

    5ml/7ml×48

    (105mm采血管)

    标配

    5000

    100ml×4

    选配

    5000

    10ml×12

    选配

    4200

    7ml×60

    选配

    2000

    96孔培养板

    选配

    DT5-3

    血库通用

    离心机

    微电脑控制,7个预选程序,分离到秒,快速启动快速停机。

    5000

    4360

    100ml×4

    标配

    5000

    10ml×12

    标配

    3500

    10 ml×32

    标配

    4200

    5ml×40

    标配

    DT5-4

    A

    原LD5-10

    低速台式

    离心机

    无刷电机,微电脑控制,可预选转速、时间、离心力,全液显,不锈钢容器室

    5000

    5180

    250ml×4

    标配

    10ml×28

    标配

    B

    原LD5-10B

    5000

    5180

    7/5ml×88

    标配

    10ml×72

    标配

    7ml×120

    标配

    500ml×4

    选配

    20ml×36

    选配

    50ml×16

    选配

    自动脱帽离心机

    4000

    3150

    75mm采血管×100

    标配

    105mm采血管×84

    标配

    Lerociclib(Synonyms: G1T38)

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

    Lerociclib (Synonyms: G1T38)

    Lerociclib (G1T38) 是一种有效的、CDK4/6 的选择性抑制剂,其对 CDK4/CyclinD1 和 CDK6/CyclinD3 的 IC50 值分别为 1 nM 和 2 nM。

    Lerociclib(Synonyms: G1T38)

    Lerociclib Chemical Structure

    CAS No. : 1628256-23-4

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    Lerociclib 的其他形式现货产品:

    Lerociclib dihydrochloride

    生物活性

    Lerociclib (G1T38) is a potent and selective inhibitor of CDK4/6, with IC50s of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.

    IC50 & Target

    cdk2/cyclin A

    1.5 μM (IC50)

    CDK2/cyclinE

    3.6 μM (IC50)

    Cdk4/cyclin D1

    1 nM (IC50)

    cdk6/cyclin D3

    2 nM (IC50)

    CDK9/Cyclin T

    28 nM (IC50)

    CDK5/p35

    0.832 μM (IC50)

    CDK1/cyclinB1

    2.4 μM (IC50)

    CDK7/Cyclin H/MAT1

    2.4 μM (IC50)

    Cdk5/p25

    1.2 μM (IC50)

    体外研究
    (In Vitro)

    Within the CDK family, Lerociclib is least selective against CDK9/cyclin T, ~30 fold between CDK4/cyclin D1 and CDK9/ cyclin T at the biochemical IC50. Lerociclib produces a robust and sustained G1 arrest in CDK4/6 dependent cells with an EC50 of ~20 nM. A dose dependent increase of cells in the G1 phase of the cell cycle is observed when CDK4/6 dependent WM2664 cells are treated with Lerociclib for 24 hours. This arrest is maintained through 300 nM, more than 300x the biochemical IC50. WM2664 cells treated with 30-1000 nM of Lerociclib for 24 hours exhibits a complete inhibition of RB phosphorylation compared to vehicle controls. Treatment with Lerociclib reduces RB phosphorylation within 1 hour post-treatment and generates near complete inhibition of RB phosphorylation by 16 hours post-treatment. Lerociclib produces a robust inhibition of proliferation in a diverse array of tumor cell lines including breast, melanoma, leukemia and lymphoma with EC50 concentrations as low as 23 nM[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    体内研究
    (In Vivo)

    In this HER2+ breast cancer model, Mice treated with Lerociclib elicits 8% tumor regression after 21 days of treatment while control animals have a 577% increase in tumor burden over the same treatment period. Compared to the vehicle-treated mice, daily treatment with 100 mg/kg of Lerocyclib or palbociclib shows tumor regression within 10 days in the MCF7 xenograft model. After 27 days of treatment, tumor growth inhibition is observed in the 10, 50, and 100 mg/kg Lerociclib cohorts (approximately 12%, 74%, and 90% inhibition, respectively). Daily oral palbociclib treatment causes an 18%, 66%, and 87% tumor growth inhibition in the 10, 50, and 100 mg/kg dosage cohorts, respectively. Interestingly, at 50 mg/kg, Lerociclib is significantly more efficaciou than palbociclib. Similar results are seen in the ER+ZR-75-1 breast cancer xenograft model when comparing Lerocyclib and palbociclib at the 50 mg/kg dose. Lerociclib treated mice exhibits 77% TGI with an overall 60% tumor growth delay demonstrating Lerocyclib alone is highly efficacious in this NSCLC tumor model.

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial

    分子量

    474.60

    Formula

    C26H34N8O

    CAS 号

    1628256-23-4

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.

    参考文献
    • [1]. Bisi JE, et al. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget. 2017 Jun 27;8(26):42343-42358.

    Cell Assay

    SupT1, Daudi, MCF7, ZR-75-1, A2058, WM2664, and H69 cells are seeded at 1000 cells per well; MV-4-11 and BV173 cells are plated at 4000 cells per well; Tom-1 cells are plated at 8,000 cells per well; NALM-1 cells are plated at 20,000 cells per well in Costar 3903 96 well plates. After 24 hours, plates are dosed with Lerociclib (G1T38) at a nine-point dose concentration from 10 μM to 1 nM. Cell viability is determined after four or six days. Plates are processed on BioTek Synergy2 multi-mode plate reader and data analyzed using GraphPad Prism 5 statistical software[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Mice[1]
    Female MMTV-NEU mice are used to test the efficacy of Lerocyclib (G1T38) (100 mpk, medicated diet). At time of treatment, body composition is assessed and weight measurements (in grams) are recorded and used as a measure of gross toxicity. Female nude mice are implanted with NSCLC PDX CTG0159 tumor. Mice are then randomized into treatment groups and dosing initiated once tumors reached a volume that fell within the range of 150-300 mm3. 100 mg/kg Lerociclib (G1T38) or vehicle is orally administered for 28 consecutive days. Female NCI Ath/nu mice are implanted with H1975 NSC lung adenocarcinoma model. Once tumors reach an average size of 100-150 mm3, mice are randomized into treatment cohorts. Mice are orally administered daily afatinib (20 mg/kg), erlotinib (70 mg/kg), or Lerociclib (50 or 100 mg/kg), as single agents or in combination (Lerociclib+erlotinib or Lerociclib+afatinib) for the duration of the study. All tumors are measured twice weekly until mice reach tumor burden of 1500 mm3.

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    参考文献
    • [1]. Bisi JE, et al. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget. 2017 Jun 27;8(26):42343-42358.

    所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

    英国Techne数字式胶凝计时器GT-5/GT-6

    【简单介绍】

    英国Techne数字式胶凝计时器GT-5/GT-6是用于实验室中树脂或粘胶剂基样品的胶化的准确测量和质量控制的理想装置。含有数字式定时器,增加单位从1分钟 (GT-5) 直到9999分钟, 或1/10分钟(GT-6)直到999.9 分钟。高亮LED显示到Z近的分钟或1/10分钟的时间,声光报警器确认胶凝结束。

    进口,!

    【详细说明】

    英国Techne数字式胶凝计时器GT-5/GT-6

    产品描述

    两种型号可供使用; 1rpm and 10rpm
    出现胶化时自动停止运行
    使用方便,按钮式显示
    可装在曲颈蒸馏器支座上,便于使用
    柱塞可拆卸,容易清洁
    提供样品杯和一次性柱塞
    3年质保

    近60年来,Techne? 一直是胶凝计时器的基准,事实上,有关这一工艺的一些英国标准均根据我们的设备而制定。胶凝计时器应用于在聚合作用中从液体转化到固体过程的测量。

       英国Techne数字式胶凝计时器GT-5/GT-6的两种型号均含有数字式定时器,增加单位从1分钟 (GT-5) 直到9999分钟, 或1/10分钟(GT-6)直到999.9 分钟。高亮LED显示到近的分钟或1/10分钟的时间,声光报警器确认胶凝结束。

    Techne? 胶凝计时器是用于实验室中树脂或粘胶剂基样品的胶化的准确测量和质量控制的理想装置。每一装置均配有常见的Techne? 质保, 包括一份校验证明。在出厂前,每一套装置均经过校正和证明。

    技术指标

    型号 GT-5 GT-6
    数字式定时器增加单位 1 min 1/10th min
    长时间 9999 minutes 999.9 minutes
    尺寸 L x W x H (mm) 94 x 69 x 119 94 x 69 x 119
    电压 230V, 50Hz 230V, 50Hz
    功率 5W 5W
    运输重量 7.7kg 7.7kg

    订货信息

    部件号 描述
    FGT5 GT-5 数字式凝胶计时器, 1rpm
    FGT6 GT-6 数字式凝胶计时器, 10rpm

    附件

    部件号 描述
    F0985 22mm不锈钢柱塞
    F0979 19mm 不锈钢柱塞
    F0982 16mm 不锈钢柱塞
    F1794 100个一次性柱塞包装
    F1795 一次性柱塞适配器
    F7846 240个样品杯包装

       

    GT16-3A台式微量高速离心机

    【简单介绍】

    品牌 其他品牌 结构类型 台式
    布局形式 立式

    GT16-3A台式微量高速离心机采用无刷电机、电脑控制、不锈钢容器室、可预选转速、时间、离心力,液晶显示、全触摸、预警报告,多种保护,新型面板设计,操作简便。该机分离效果好、安全可靠。广泛用于生物学、农业科学及临床医学研究,特别适用于样品量少,要求离心力大的实验工作。

    【详细说明】

    GT16-3A台式微量高速离心机

    产品简述:

      GT16-3A台式微量高速离心机采用直流无刷电机,免维护;微电脑控制,可预选转速、时间、离心力,液晶显示,操作简便;预警报警、多种保护;不锈钢容器室,电子门锁,安全可靠。该机分离效果好、安全可靠。广泛用于生物学、农业科学及临床医学研究,特别适用于样品量少,要求离心力大的实验工作。适用于PCR、分子生物等样本较少的分离。

     

    技术参数:

    型号

    Model

    容量Capacity

    高转速

    Max speed

    大离心力

    Max RCF

    定时范围

    Time Range

    外形尺寸

    Dimension

    重量

    Weight

    GT16-3A   微量

    1.5ml×12 标配

    16000r/min

    17100×g

    1-999min

    31×24×20(cm)

    18kg

     

    转子图片:

     

     

    同系列相关产品:

    型号

    产品名称

    功能特点

    高转速(r/min)

    大离心力(×g)

    容量

    (ml)

    说明

    GT16-3M

    迷你离心机

     

    7200

    2350

    2ml/1.5ml×6

    0.2ml × 8×2

    标配

    GT16-3A

    高速微量离心机

    无刷电机,微电脑控制,可预选转速、时间、离心力,全液显,不锈钢容器室

    16000

    17100

    1.5ml×12

    标配

    GT16-3

    高速台式

    离心机

     

    16000

    17930

    1.5ml×12

    标配

     

     

     

    16000

     

    0.5ml×12

    选配

     

     

     

    15000

     

    5ml×12

    选配

     

     

     

    13000

     

    7ml×10

    选配

     

     

     

    13000

     

    1.5ml×24

    选配

     

     

     

    13000

     

    0.5ml×48

    选配

    GTR10-1

    高速台式冷冻离心机

    无刷电机,微电脑控制,可预选转速、时间、离心力,全数显,进口制冷机组

    5000

    4360

    100 ml×4

    标配

     

     

     

    4200

    3400

    50ml×8

    标配

     

     

     

    4200

    3400

    15ml×16

    标配

     

     

     

    10000

    11000

    50ml×6角转子

    选配

    GTR10-2

    高速冷冻

    离心机

    无刷电机,微电脑控制,可预选转速、时间、离心力,全液显,进口制冷机组

    5000

    5180

    500 ml×4

    标配

     

     

     

     

     

    10 ml×72

     

     

     

     

     

    5ml×88

     

     

     

     

     

    7 ml×120

    选配

     

     

     

     

     

    20ml×36

    选配

     

     

     

     

     

    50ml×16

    选配

    GTR16-1

    高速台式冷冻

    离心机

     

    16000

    17930

    1.5/2ml×12

    标配

     

     

     

     

     

    0.5ml×12

    选配

    GTR16-2

    高速台式冷冻

    离心机

    无刷电机,微电脑控制,可预选转速、时间、离心力,全数显,进口制冷机组

    16000

    17930

    1.5/2ml×12

    标配

     

     

     

    15000

     

    5ml×12

    选配

     

     

     

    13000

     

    7ml×10

    选配

     

     

     

    13000

     

    1.5ml×24

    选配

     

     

     

    10000

     

    10ml×12

    选配

     

     

     

    10000

     

    50ml×6

    选配

     

     

     

    10000

     

    100ml×4

    选配

    GTR221

    高速台式冷冻

    离心机

    无刷电机,微电脑控制,可预选转速、时间、离心力,全数显,进口制冷机组

    22000

    33900

    1.5ml×12

    标配

     

     

     

    22000

     

    0.5ml×12

    选配

     

     

     

    15000

     

    5ml×12

    选配

     

     

     

    13000

     

    7ml×10

    选配

     

     

     

    13000

     

    1.5ml×24

    选配

     

     

     

    13000

     

    0.5ml×48

    选配

     

     

     

    10000

     

    10ml×24

    选配

    GT10-1台式高速离心机

    【简单介绍】

    品牌 其他品牌 结构类型 台式
    布局形式 立式

    GT10-1台式高速离心机采用直流无刷电机,免维护;微电脑控制,可预选转速、时间、离心力,液晶显示,操作简便;10种升降速率供选择,可快速启动、快速停机;不锈钢容器室,电子门锁,预警报警功能,多种保护,安全可靠。是医疗卫生、食品、环保、科研、教学的优选离心设备。

    【详细说明】

    GT10-1台式高速离心机

    产品简述:

      GT10-1(原LG10-2.4A)台式高速离心机采用直流无刷电机,免维护;微电脑控制,可预选转速、时间、离心力,液晶显示,操作简便;10种升降速率供选择,可快速启动、快速停机;不锈钢容器室,电子门锁,预警报警功能,多种保护,安全可靠。是医疗卫生、食品、环保、科研、教学的优选离心设备。

    技术参数:整机功率:750W

    型号

    Model

    z高转速

    Max speed

    z大离心力

    Max RDF

    整机功率  Machine Power  

    定时范围

    Time Range

    外形尺寸

    Dimension

    重量

    Weight

    GT10-1

    10000r/min

    11000×g

    750W

    1-999min

    51×41×31(cm)

    36kg

    转子参数:

    容量Capacity

    z高转速Max speed

    备注

    50ml×6

    10000r/min

    标配

    100ml×4

    10000r/min

    选配

    10ml×12

    10000r/min

    选配

    10ml×24

    10000r/min

    选配

    15ml×12

    10000r/min

    选配

    GT10-1台式高速离心机

    转子图片:

    ARKRAY京都 血糖仪GT-1920

    ARKRAY京都 血糖仪GT-1920

    ARKRAY京都 血糖仪GT-1920

  • 商品品牌: ARKRAY京都
    商品编号:GT-1920
  • 商品价格: 请与我们联系
  • ARKRAY京都 血糖仪GT-1920-ARKRAY京都-GT-1920

    • 最少样本量:0.3微升
    • 测定时间:≤10S
    • 品牌属性:进口
    生命科学仪器|||生化免疫|||血糖分析仪|||ARKRAY京都血糖仪GT-1920
    血糖分析仪

    ARKRAY京都 血糖仪GT-1920 详细描述:

    操作简单

    性价比高

    高速测定 极微量采血

    商品属性

    • 最少样本量:0.3微升
    • 测定时间:≤10S
    • 品牌属性:进口
    商品属性
    商品名称 ARKRAY京都 血糖仪GT-1920-GT-1920-ARKRAY京都
    型号 GT-1920
    类别 生命科学仪器|||生化免疫|||血糖分析仪|||ARKRAY京都血糖仪GT-1920
    品牌 ARKRAY京都
    品牌简介 ARKRAY京都
    关键字 血糖分析仪,京都,样本,时间,血糖仪,血糖,性价比

    ARKRAY京都 血糖仪GT-1920